BRKB

480.35

-0.22%↓

BRKA.US

720,335.7

-0.21%↓

JPM

289.94

+1.14%↑

V

304.19

+0.85%↑

MA

500.63

+0.99%↑

BRKB

480.35

-0.22%↓

BRKA.US

720,335.7

-0.21%↓

JPM

289.94

+1.14%↑

V

304.19

+0.85%↑

MA

500.63

+0.99%↑

BRKB

480.35

-0.22%↓

BRKA.US

720,335.7

-0.21%↓

JPM

289.94

+1.14%↑

V

304.19

+0.85%↑

MA

500.63

+0.99%↑

BRKB

480.35

-0.22%↓

BRKA.US

720,335.7

-0.21%↓

JPM

289.94

+1.14%↑

V

304.19

+0.85%↑

MA

500.63

+0.99%↑

BRKB

480.35

-0.22%↓

BRKA.US

720,335.7

-0.21%↓

JPM

289.94

+1.14%↑

V

304.19

+0.85%↑

MA

500.63

+0.99%↑

Search

Jackson Financial Inc (Class A)

Gesloten

SectorFinanciën

104.5 1.54

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

102.45

Max

107.32

Belangrijke statistieken

By Trading Economics

Inkomsten

58M

149M

Verkoop

745M

2.1B

K/W

Sectorgemiddelde

15.351

54.048

EPS

6.61

Dividendrendement

3.08

Winstmarge

7.116

Werknemers

3,090

EBITDA

-430M

-333M

Aanbevelingen

By TipRanks

Aanbevelingen

Buy

12 Maanden Prognose

+15.16% upside

Dividenden

By Dow Jones

Dividendrendement

Sectorgemiddelde

3.08%

4.84%

Volgende Winsten

6 mei 2026

Volgende dividenddatum

26 mrt 2026

Volgende Ex Dividend datum

11 jun 2026

Marktinformatie

By TradingEconomics

Marktkapitalisatie

-610M

7.3B

Vorige openingsprijs

102.96

Vorige sluitingsprijs

104.5

Nieuwssentiment

By Acuity

20%

80%

24 / 441 Rangschikking in Finance

Technische score

By Trading Central

Vertrouwen

Bullish Evidence

Jackson Financial Inc (Class A) Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

23 mrt 2026, 23:47 UTC

Acquisities, Fusies, Overnames

Gilead Sciences to Buy Ouro Medicines, Collaborate With Galapagos on Purchased Assets -- Update

23 mrt 2026, 22:55 UTC

Acquisities, Fusies, Overnames

Gilead Sciences to Buy Ouro Medicines for Up to $2.18 Billion

23 mrt 2026, 21:51 UTC

Acquisities, Fusies, Overnames

Italy's Postal Service Makes $12.50 Billion Bid for Telecom Italia -- 3rd Update

23 mrt 2026, 23:59 UTC

Marktinformatie

Global Equities Roundup: Market Talk

23 mrt 2026, 23:59 UTC

Marktinformatie

Woodside, Santos Earnings Power Up on Surging LNG Prices -- Market Talk

23 mrt 2026, 23:50 UTC

Marktinformatie

Nikkei May Rise on Hopes for U.S. Talks With Iran -- Market Talk

23 mrt 2026, 23:37 UTC

Marktinformatie

Gold Rises, Boosted by Fall in Dollar, U.S. Treasury Yields -- Market Talk

23 mrt 2026, 22:42 UTC

Marktinformatie
Belangrijke Nieuwsgebeurtenissen

Global Equities Roundup: Market Talk

23 mrt 2026, 22:42 UTC

Marktinformatie
Belangrijke Nieuwsgebeurtenissen

Bell Potter Names Miners Less Exposed to Fuel Price, Supply Risks -- Market Talk

23 mrt 2026, 22:40 UTC

Acquisities, Fusies, Overnames

Gilead Sciences to Buy Ouro Medicines for Up to $2.18B

23 mrt 2026, 22:23 UTC

Marktinformatie

Apollo Debt Solutions Shrugs Off Private-Credit Fears -- Market Talk

23 mrt 2026, 22:22 UTC

Acquisities, Fusies, Overnames

Gilead Sciences: OM336 Is for Treatment of Autoantibodies Driven Immune-Mediated Disease

23 mrt 2026, 22:21 UTC

Acquisities, Fusies, Overnames

Gilead Sciences: Company Would Pay Galapagos Royalties of 20%-23% of Net OM336 Sales

23 mrt 2026, 22:21 UTC

Acquisities, Fusies, Overnames

Gilead Sciences: Company Would Retain Sole Worldwide Commercialization Rights of OM336 Outside of Greater China

23 mrt 2026, 22:20 UTC

Acquisities, Fusies, Overnames

Gilead Sciences: Company, Galapagos Would Collaborate on Development of OM336 >GILD

23 mrt 2026, 22:20 UTC

Acquisities, Fusies, Overnames

Gilead Sciences: Galapagos Would Absorb Substantially All of Ouro's Operating Assets, Retain Its Employees >GILD

23 mrt 2026, 22:19 UTC

Acquisities, Fusies, Overnames

Gilead Sciences: Galapagos Would Pay 50% of Upfront Consideration and 50% of Any Contingent Milestone Payments Payable to Ouro Shareholders

23 mrt 2026, 22:19 UTC

Acquisities, Fusies, Overnames

Gilead Sciences: Currently in Advanced Discussions With Galapagos With Respect to Potential Research-and-Development Collaboration on Acquired Ouro Assets

23 mrt 2026, 22:18 UTC

Acquisities, Fusies, Overnames

Gilead Sciences to Buy Ouro Medicines for About $1.68B Upfront, Up to $500M in Contingent Milestone Payments >GILD

23 mrt 2026, 22:15 UTC

Acquisities, Fusies, Overnames

Gilead Sciences To Acquire Ouro Medicines To Advance First In Class T Cell Engager Program For Autoimmune Diseases >GILD

23 mrt 2026, 22:08 UTC

Marktinformatie

Ebos Needs to Reset Its Gearing Targets -- Market Talk

23 mrt 2026, 21:42 UTC

Marktinformatie

Global Forex and Fixed Income Roundup: Market Talk

23 mrt 2026, 21:42 UTC

Marktinformatie

RBNZ's Breman Strikes Reassuring Tone On Rates -- Market Talk

23 mrt 2026, 21:32 UTC

Winsten

WuXi XDC Cayman: Results Aided by Strong Growth in Contract Research, Development and Manufacturing Organisation Business>2268.HK

23 mrt 2026, 21:32 UTC

Winsten

WuXi XDC Cayman 2025 Net CNY1.56B Vs. Net CNY917.16M >2268.HK

23 mrt 2026, 21:32 UTC

Winsten

WuXi XDC Cayman 2025 Rev CNY5.94B Vs. CNY4.05B >2268.HK

23 mrt 2026, 21:10 UTC

Belangrijke Nieuwsgebeurtenissen

Oil Is Back Under $100. Trump Says Iran Has Agreed to No Nuclear Weapons. -- Barrons.com

23 mrt 2026, 20:50 UTC

Marktinformatie

Tech, Media & Telecom Roundup: Market Talk

23 mrt 2026, 20:50 UTC

Marktinformatie

Health Care Roundup: Market Talk

23 mrt 2026, 20:50 UTC

Marktinformatie
Winsten
Belangrijke Nieuwsgebeurtenissen

Basic Materials Roundup: Market Talk

Peer Vergelijking

Prijswijziging

Jackson Financial Inc (Class A) Prognose

Koersdoel

By TipRanks

15.16% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 118.67 USD  15.16%

Hoogste 138 USD

Laagste 100 USD

Gebaseerd op 3 Wall Street-analisten die 12-maands prijsdoelen bieden voor Jackson Financial Inc (Class A) - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Buy

3 ratings

1

Buy

2

Hold

0

Sell

Technische score

By Trading Central

76.83 / N/ASteun & Weerstand

Korte Termijn

Bullish Evidence

Gemiddeld Termijn

Bearish Evidence

Lange Termijn

Strong Bearish Evidence

Sentiment

By Acuity

24 / 441 Rangschikking in Financiën

Nieuwssentiment

Zeer Sterk Bearish Bewijs

Volatiliteit

Onder gemiddelde

Nieuws Volume (RCV)

Onder gemiddelde

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Jackson Financial Inc (Class A)

Jackson Financial Inc., through its subsidiaries, provides suite of annuities to retail investors in the United States. The company operates through three segments: Retail Annuities, Institutional Products, and Closed Life and Annuity Blocks. The Retail Annuities segment offers various retirement income and savings products, including variable, fixed index, fixed, and payout annuities, as well as registered index-linked annuities and lifetime income solutions. The Institutional Products segment provides traditional guaranteed investment contracts; funding agreements comprising agreements issued in conjunction with its participation in the U.S. federal home loan bank program; and medium-term funding agreement-backed notes. The Closed Life and Annuity Blocks segment offers various protection products, such as whole life, universal life, variable universal life, and term life insurance products, as well as fixed, fixed index, and payout annuities; and a block of group payout annuities. The company also offers investment management services. It sells its products through a distribution network that includes independent broker-dealers, wirehouses, regional broker-dealers, banks, independent registered investment advisors, third-party platforms, and insurance agents. The company was formerly known as Brooke (Holdco1) Inc. and changed its name to Jackson Financial Inc. in July 2020. Jackson Financial Inc. was incorporated in 2006 and is headquartered in Lansing, Michigan.
help-icon Live chat